Patent delisted for Taiho Oncology drug LONSURF

Copyright © DrugPatentWatch. Originally published at

Annual Drug Patent Expirations for LONSURF
Lonsurf is a drug marketed by Taiho Oncology and is included in one NDA. It is available from one supplier. There are five patents protecting this drug.

This drug has seventy-six patent family members in thirty-one countries.

The generic ingredient in LONSURF is tipiracil hydrochloride; trifluridine. One supplier is listed for this compound. Additional details are available on the tipiracil hydrochloride; trifluridine profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact or visit

Make Better Decisions with DrugPatentWatch

» Start Your Free Trial Today «

Copyright © DrugPatentWatch. Originally published at
DrugPatentWatch - Make Better Decisions
Scroll to Top